Investigation of genetic variants of α-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry

Lívia Budai, Oliver Ozohanics, K. Ludányi, L. Drahos, T. Kremmer, Judit Krenyacz, K. Vékey

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Genetic variants of human plasma alpha-1 acid glycoprotein (AGP) have been studied in cancer, compared with a group of healthy control. AGP has four genetic variants: AGP F1, F2, and S variants correspond to the ORM1 gene whereas AGP A corresponds to the ORM2 gene. The proportion of ORM1 and ORM2 variants were studied in plasma using a novel UPLC-MS method. Plasma total AGP level was 0.5∈±∈0.2 g L-1 and the proportions of the ORM1 and ORM2 variants were 76.3∈±∈8.2% and 23.7∈±∈8. 2%, respectively. In cancer plasma AGP levels increased fourfold and the proportion of ORM1 variants increased to 88.7∈±∈6.8%. Changes in the proportion of genetic variants due to cancer were clearly significant, as shown by statistical analysis. Three different cancer types have been studied, lymphoma, melanoma, and ovarian cancer. The results did not show any difference depending on cancer type. The results indicate that, in accordance with prior expectations, the ORM1 variant is predominantly responsible for the acute-phase property of AGP.

Original languageEnglish
Pages (from-to)991-998
Number of pages8
JournalAnalytical and Bioanalytical Chemistry
Volume393
Issue number3
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Liquid chromatography
Liquid Chromatography
Mass spectrometry
Mass Spectrometry
Glycoproteins
Acids
Neoplasms
Plasmas
Genes
Plasma (human)
Orosomucoid
Medical Genetics
Ovarian Neoplasms
Melanoma
Lymphoma
Statistical methods
Control Groups

Keywords

  • Alpha-1 acid glycoprotein
  • Cancer
  • Genetic variant
  • Peptide marker
  • UPLC-MS

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Investigation of genetic variants of α-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry. / Budai, Lívia; Ozohanics, Oliver; Ludányi, K.; Drahos, L.; Kremmer, T.; Krenyacz, Judit; Vékey, K.

In: Analytical and Bioanalytical Chemistry, Vol. 393, No. 3, 02.2009, p. 991-998.

Research output: Contribution to journalArticle

@article{fbd15921f753495a98aca83eae86ce5d,
title = "Investigation of genetic variants of α-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry",
abstract = "Genetic variants of human plasma alpha-1 acid glycoprotein (AGP) have been studied in cancer, compared with a group of healthy control. AGP has four genetic variants: AGP F1, F2, and S variants correspond to the ORM1 gene whereas AGP A corresponds to the ORM2 gene. The proportion of ORM1 and ORM2 variants were studied in plasma using a novel UPLC-MS method. Plasma total AGP level was 0.5∈±∈0.2 g L-1 and the proportions of the ORM1 and ORM2 variants were 76.3∈±∈8.2{\%} and 23.7∈±∈8. 2{\%}, respectively. In cancer plasma AGP levels increased fourfold and the proportion of ORM1 variants increased to 88.7∈±∈6.8{\%}. Changes in the proportion of genetic variants due to cancer were clearly significant, as shown by statistical analysis. Three different cancer types have been studied, lymphoma, melanoma, and ovarian cancer. The results did not show any difference depending on cancer type. The results indicate that, in accordance with prior expectations, the ORM1 variant is predominantly responsible for the acute-phase property of AGP.",
keywords = "Alpha-1 acid glycoprotein, Cancer, Genetic variant, Peptide marker, UPLC-MS",
author = "L{\'i}via Budai and Oliver Ozohanics and K. Lud{\'a}nyi and L. Drahos and T. Kremmer and Judit Krenyacz and K. V{\'e}key",
year = "2009",
month = "2",
doi = "10.1007/s00216-008-2518-6",
language = "English",
volume = "393",
pages = "991--998",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "1618-2642",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Investigation of genetic variants of α-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry

AU - Budai, Lívia

AU - Ozohanics, Oliver

AU - Ludányi, K.

AU - Drahos, L.

AU - Kremmer, T.

AU - Krenyacz, Judit

AU - Vékey, K.

PY - 2009/2

Y1 - 2009/2

N2 - Genetic variants of human plasma alpha-1 acid glycoprotein (AGP) have been studied in cancer, compared with a group of healthy control. AGP has four genetic variants: AGP F1, F2, and S variants correspond to the ORM1 gene whereas AGP A corresponds to the ORM2 gene. The proportion of ORM1 and ORM2 variants were studied in plasma using a novel UPLC-MS method. Plasma total AGP level was 0.5∈±∈0.2 g L-1 and the proportions of the ORM1 and ORM2 variants were 76.3∈±∈8.2% and 23.7∈±∈8. 2%, respectively. In cancer plasma AGP levels increased fourfold and the proportion of ORM1 variants increased to 88.7∈±∈6.8%. Changes in the proportion of genetic variants due to cancer were clearly significant, as shown by statistical analysis. Three different cancer types have been studied, lymphoma, melanoma, and ovarian cancer. The results did not show any difference depending on cancer type. The results indicate that, in accordance with prior expectations, the ORM1 variant is predominantly responsible for the acute-phase property of AGP.

AB - Genetic variants of human plasma alpha-1 acid glycoprotein (AGP) have been studied in cancer, compared with a group of healthy control. AGP has four genetic variants: AGP F1, F2, and S variants correspond to the ORM1 gene whereas AGP A corresponds to the ORM2 gene. The proportion of ORM1 and ORM2 variants were studied in plasma using a novel UPLC-MS method. Plasma total AGP level was 0.5∈±∈0.2 g L-1 and the proportions of the ORM1 and ORM2 variants were 76.3∈±∈8.2% and 23.7∈±∈8. 2%, respectively. In cancer plasma AGP levels increased fourfold and the proportion of ORM1 variants increased to 88.7∈±∈6.8%. Changes in the proportion of genetic variants due to cancer were clearly significant, as shown by statistical analysis. Three different cancer types have been studied, lymphoma, melanoma, and ovarian cancer. The results did not show any difference depending on cancer type. The results indicate that, in accordance with prior expectations, the ORM1 variant is predominantly responsible for the acute-phase property of AGP.

KW - Alpha-1 acid glycoprotein

KW - Cancer

KW - Genetic variant

KW - Peptide marker

KW - UPLC-MS

UR - http://www.scopus.com/inward/record.url?scp=59249102890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249102890&partnerID=8YFLogxK

U2 - 10.1007/s00216-008-2518-6

DO - 10.1007/s00216-008-2518-6

M3 - Article

C2 - 19018521

AN - SCOPUS:59249102890

VL - 393

SP - 991

EP - 998

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 1618-2642

IS - 3

ER -